TABLE 7.
Value and value share estimates for NICE approved products
| Product | FAD ICER (£/QALY) | Total potential net health effects (net QALYs) | Realized population net health effects (net QALYs) | Health foregone due to payments to manufacturers (net QALYs) | Share of value accruing as population health gains (%) | Share of value accruing to manufacturer (%) |
|---|---|---|---|---|---|---|
| Nalmefene | 1110 | 80,460 | 73,188 | 7271 | 91 | 9 |
| Vortioxetine | 2970 | 37,758 | 35,165 | 2593 | 93 | 7 |
| Rivaroxaban | 5622 | 30,605 | 28,774 | 1831 | 94 | 6 |
| Thalidomide | 9174 | 68,772 | 55,693 | 13,079 | 81 | 19 |
| Adalimumab | 19,328 | 2038 | −292 | 2330 | −14 | 114 |
| Vedolizumab | 21,620 | 991 | −432 | 1423 | −44 | 144 |
| Enzalutamide (pre‐chemotherapy) | 32,985 | 124,410 | 26,176 | 98,234 | 21 | 79 |
| Pembrolizumab (NSCLC) | 44,490 | 16,360 | −26,126 | 42,486 | −160 | 260 |
| Cabazitaxel | 45,159 | 2510 | −456 | 2966 | −18 | 118 |
| Enzalutamide (post‐chemotherapy) | 45,626 | 1521 | −1036 | 2557 | −68 | 168 |
| Pembrolizumab (melanoma) | 46,662 | 3717 | −5312 | 9029 | −143 | 243 |
| Olaparib | 46,973 | 4317 | −2078 | 6394 | −48 | 148 |
| Total | ‐ | 373,458 | 183,265 | 190,193 | 49 | 51 |
Note: FAD, final appraisal determination; ICER, incremental cost‐effectiveness ratio; NICE, National Institute for Health and Care Excellence; NSCLC, non‐small‐cell lung cancer; QALY, quality‐adjusted life year.